←
Ralph Isberg4,565 posts
Ralph Isberg avatar

Ralph Isberg

@IsbergRalph

Microbiologist and Icerink Connoisseur. . .Humor expressed not necessarily my own. Militantly antagonistic to full justification formatting.

◷ Joined November 2019▧ 299 Photos and videos
Ralph Isberg avatar
Ralph Isberg@IsbergRalph·Nov 6

A brilliant tweet giving subtle reference to multiple ancient calendars and contemporary events. Follow Mahmud

הגעתי למאפיית חנטושי באו''ם אל פחם כדי לקנות ביתות (פ) חמות לארוחה של יום אלג׳ומעה (שישי). הבת שלי מתקשרת אלי. באבא? - יא רוח באבא ( הנשמה של של אבא). תקנה לי - לחמניות? לא. - בגטים? לא. -פיצה? לא. -מה לקנות לך? סופגניות באבא. סופגניות עם תטלי (ריבה). סופ''ש מתוק כמו סופגניה♥️

Post attachment
Bloom Lab avatar
⟳ Ralph Isberg retweeted
Bloom Lab@jbloom_lab·Oct 21

In new study, we show that SARS-CoV-2 has evolved decreased inherent antigenicity in humans, as quantified by a ~3-fold decrease in the number of naïve human B cells that can bind the spike RBD. doi.org/10.64898/2026.10.15.…

Shai Bel avatar
⟳ Ralph Isberg retweeted
Shai Bel@Mucus_Man·Oct 19

🚨🚨 When we take antibiotics we assume they'll kill the bad bugs but won't affect us directly. In our new story @NatureMicrobiol , we found that's not always the case and developed a tool, CompoRes, to identify these direct effects on the host /1 nature.com/articles/s41564-0…

Andrew Kern avatar
⟳ Ralph Isberg retweeted
Andrew Kern@pastramimachine·Oct 18

We are searching for a new colleague in our Department of Biology at University of Oregon! This is a super special opportunity-- an endowed chair position in Genetics/Genomics. Come join us! I'm happy to answer any questions folks might have careers.pageuppeople.com/726…

Ralph Isberg avatar
Ralph Isberg@IsbergRalph·Oct 8

Flagellin-induced pyroptosis, which tortured my research projects 25 years ago, continues to torture me when I get a SARS-CoV-2 vaccine? Just in time for Pyrotech in China to start testing gasdermin inhibitors.

New @ScienceMagazine A breakthrough in understanding why we get fever and an inflammation response to vaccines. The gut microbiome chronic production of flagellin Paves the way to potentially prevent these acute phase side-effects in the future science.org/doi/10.1126/scie…

Post attachment
Eric Topol avatar
⟳ Ralph Isberg retweeted
Eric Topol@EricTopol·Oct 6

Published today, there's a lot in Michael Lewis's new book we didn't know about. Including the NIH, unbridled assertion of power, and many civil servant heroes (the "blockers") erictopol.substack.com/p/mic…

0:28
Ashish K. Jha avatar
⟳ Ralph Isberg retweeted
Ashish K. Jha@ashishkjha·Oct 5

Many of you have been tracking the Irkutsk lab situation over the last few days. I've been gathering facts and trying to understand what is happening before weighing in. Now that I have, I have to say — I'm concerned 🧵

Ansu Satpathy avatar
⟳ Ralph Isberg retweeted
Ansu Satpathy@Satpathology·Sep 19

Cell–cell interactions are key to all biological processes, but there hasn't been a good way to perform inter-cellular screens for genetic regulators of these interactions in vivo. We developed match-seq (multiplexed associative tagging of cell interaction histories) - using engineered virus-like particles to transfer barcoded mRNAs from 'sender' to neighboring 'receiver' cells, so you can reconstruct cellular interactions with sequencing alone, no imaging required. We coupled match-seq with CRISPR + scRNA-seq in cancer, revealing cancer-immune interaction neighborhoods at scale, and new cancer genes that can be targeted for tumor rejection via immune cell interactions. Led by the brilliant @peterdu_ with Bassik lab! biorxiv.org/content/10.64898…

Post attachment

CRISPR screens are great at telling you what a gene is doing inside your cells. But what if you're interested in what's happening to its neighbors? Today, I'm excited to share match-seq, a new method that deciphers cell-cell interactions using barcoded RNA transfer. 1/9

Post attachment
Adam Rochussen avatar
⟳ Ralph Isberg retweeted
Adam Rochussen@AdamRochussen·Sep 1

Wow. Yet another live-cell RNA-sequencing technology. The classic criticism of transcriptomics as being an "autopsy" (measuring end-states, not trajectories) is become less and less valid. Cool stuff!

Post attachment

Now online! Live-cell transcriptomics with engineered virus-like particles dlvr.it/TVH0VM

Eitan Hersh avatar
⟳ Ralph Isberg retweeted
Eitan Hersh@eitanhersh·Aug 21

Through the Center for Expanding Viewpoints at Tufts, we’re supporting 10 courses/reading groups this fall, including many taught by our new class of postdoctoral fellows. More here: cevihe.org/august2026newslet…

Bo Wang avatar
⟳ Ralph Isberg retweeted
Bo Wang@BoWang87·Aug 20

Moderna/Merck just ran a 1,137-patient Phase 3 trial where every single dose was unique to that patient's tumor. It worked. The pipeline: surgical resection → whole exome + RNA sequencing → ML neoantigen ranking → mRNA encoding up to 34 patient-specific targets → manufactured and shipped in 8 weeks. One drug, different sequence for every patient. The ML step is worth to note: the algorithm ingests WES + RNA-seq to identify somatic mutations, then predicts which of those will actually be immunogenic, ie, displayed on tumor cell surface and trigger a T-cell response. It's designed to keep learning from accumulated clinical and immunogenicity data across patients, not just per-patient. INTerpath-001 (Stage IIB-IV resected melanoma, 2:1 randomized): combination with pembrolizumab beat Keytruda alone on both primary (RFS) and key secondary (DMFS) at interim. Phase 2b at ASCO 2026 showed 49% reduction in recurrence/death, 59% in distant metastasis/death at 5 years. Phase 3 confirmed both. What this validates: — tumor-specific neoantigen prediction by ML works in a blinded trial at scale — 8-week personalized mRNA manufacturing is operationally real — effect is additive on PD-1 blockade, not redundant This is first positive Ph3 for individualized neoantigen therapy. First positive Ph3 for any mRNA cancer therapeutic. What a great time to live in!! This is the best time for AI & biotech!

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma. Read more:

Post attachment
Arjun Raj avatar
⟳ Ralph Isberg retweeted
Arjun Raj@arjunrajlab·Jul 30

There has been a slow but seemingly inexorable industrialization of academic science that, while apparently laudable for its “practicality”, risks stamping out that which makes academic science beautiful and precious to begin with.